Invest New Drugs 2020 Feb 01
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells.
Qu F, Gu Y, Wang Q, He M, Zhou F, Sun J, Wang G, Peng Y
Proxalutamide is a newly developed androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (PCa) that has entered ...
Read More
Source: PubMed
World J Urol 2020 Feb 01
Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial.
Bultijnck R, Deforche B, Borrey N, Van Bauwel J, Lievens M, Rammant E, Fonteyne V, Decaestecker K, Steyaert A, Lumen N, Ost P
To determine the start exercise prescription dose in metastatic castrate-resistant prostate cancer (mCRPC) patients receiving second-line hormone trea ...
Read More
Source: PubMed
Clin Genitourin Cancer 2019 Dec 13
Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Mori K, Janisch F, Mostafaei H, Lysenko I, Karakiewicz PI, Enikeev DV, Briganti A, Kimura S, Egawa S, Shariat SF
The purpose of this study was to assess the prognostic value of hemoglobin (Hb) in patients with metastatic hormone-sensitive prostate cancer (HSPC). ...
Read More
Source: PubMed
Vet Surg 2020 Jan 31
Evaluation of three ligatures in simulated equine open castration.
Gandini M, Comino F, Caramello V, Giusto G
To compare three surgical knots for preventing leakage from the vascular bundle during ligation in simulated equine open castrations. ...
Read More
Source: PubMed
Cell Biol. Toxicol. 2020 Jan 30
Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain.
Peng S, Wang J, Chen H, Hu P, He XL, He Y, Wang M, Tang W, He Q, Wang YY, Xie J, Guo D, Ren S, Liu M, Qiu WW, Yi Z
Androgen deprivation therapy (ADT) via surgical or chemical castration frequently fails to halt lethal castration-resistant prostate cancer (CRPC), wh ...
Read More
Source: PubMed
